Gastric Cancer Models in Nonhuman Primates
Author Information
Author(s): Borges da Costa Joana de Fátima Ferreira, Leal Mariana Ferreira, Silva Tanielly Cristina Raiol, Andrade Junior Edilson Ferreira, Rezende Alexandre Pingarilho, Carneiro Muniz José Augusto Pereira, Lacreta Junior Antonio Carlos Cunha, Assumpção Paulo Pimentel, Calcagno Danielle Queiroz, Demachki Samia, Rabenhorst Silvia Helena Barem, Smith Marília de Arruda Cardoso, Burbano Rommel Rodriguez
Primary Institution: Universidade Federal do Pará, Brazil
Hypothesis
Canova immunomodulator can enhance the immune response and reduce adverse effects of anticancer treatments in gastric carcinogenesis models.
Conclusion
The study established two gastric carcinogenesis models in nonhuman primates, demonstrating the potential of these models for studying gastric cancer and the effects of treatments.
Supporting Evidence
- All animals inoculated with ACP03 developed gastric cancer by the 9th day.
- Five out of six animals treated with MNU died before developing cancer.
- Canova treatment restored several hematologic measurements in the surviving animal.
Takeaway
Researchers created two models of stomach cancer in monkeys to learn more about the disease and test a treatment that might help with side effects.
Methodology
The study involved inoculating monkeys with a gastric cancer cell line and treating some with a carcinogen, followed by various clinical and biochemical analyses.
Potential Biases
Potential bias due to the small number of animals and the specific conditions of the study.
Limitations
The study was limited by the small sample size and the fact that only one animal was evaluated for the Canova treatment.
Participant Demographics
36 adult Cebus apella monkeys, aged 6-7 years.
Statistical Information
P-Value
p<0.05
Confidence Interval
95%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website